Solid-State MAPD Photo Detectors Achieve Commercial Production Status

Zecotek Announces Significant Manufacturing Breakthrough With Solid-State MAPD Photo Detectors

Singapore, February 9, 2012 – Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I),a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that it has achieved commercial production status with its most advanced solid-state Micro-pixel Avalanche Photo Diode (MAPD) photo detectors MAPD-3N. The MAPDs are manufactured under contract by the Malaysian Institute of Microelectronic Systems and Omega Semiconductor Sdn Bhd (MIMOS). Fine tuning of pre-production runs over the last 6 months has resulted in MIMOS stabilizing the manufacturing process and the MAPD-3N is now ready for commercial production.

“MIMOS has done a commendable job stabilizing the manufacturing process of our proprietary MAPD photo detectors which are now ready for commercial production,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek. “The MAPD-3N features superior photon detection efficiency, energy and timing resolutions and working gain when compared to existing photo multiplier tubes (PMT). These areonreached mutual agreement critical requirements for PET (positron emission tomography) scanning devices and high energy physics applications. Customers of our solid-state MAPD photo detectors are impressed with the performance and cost advantage offered and we are now in the position to deliver units on a commercial basis.”

Zecotek’s proprietary MAPD-3N is a design upgrade of the previously announced MAPD which offers significant performance advantages over competing photomultiplier tubes (PMT). The solid-state MAPD photo detector features the highest linearity and dynamic response as compared to existing PMTs. The improvement in photon detection efficiency and working gain by a factor of 2, and the reduction of dark count rates by almost a factor of two, make the universal adoption of solid-state detection technology in advanced, high-resolution PET medical scanners and gamma camera applications, a reality, particularly when the MAPD-3Ns are matched with Zecotek’s patented LFS scintillation materials. Zecotek’s pioneering MAPD technology can be used to manufacture two-dimensional arrays of solid-state photo detectors, another significant advancement, which allows for the manufacture and implementation of both very large-area detectors and compact position-sensitive arrays, which will likely displace expensive and bulky position-sensitive PMT’s.

The MAPD-3N is supplied to customers through Zecotek Imaging Systems Pte. Ltd., Singapore, a wholly owned subsidiary of Zecotek Photonics Inc., and manufactured under contract by the Malaysian Institute of Microelectronic Systems and Omega Semiconductor Sdn Bhd.

-30-

About MIMOS
MIMOS is the premier applied research centre in frontier technologies aimed at growing globally competitive indigenous industries. MIMOS pursues exploratory and industry-driven applied research through multi-stakeholder smart partnerships with local and international universities, research institutes and industries and the Malaysia Government with a focus on frontier technologies. MIMOS’ applied research / technology areas are refined into nine (9) technology clusters – Advanced Informatics, Advanced Information Security, Advanced Analysis and Modeling, Green Technology, Grid Computing, Knowledge Technology, Micro Systems & MEMS, Nano Electronics and Wireless Communications. For more information visit: www.mimos.my.

About Zecotek
Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing high-performance crystals, photo detectors, medical lasers, optical imaging and 3D display technologies for commercial applications in the medical diagnostics and high-tech industry. Founded in 2003, the company has three distinct operating divisions: medical imaging, medical lasers and 3D display and labs located in Canada, Singapore and Russia. Zecotek commercializes its novel, patented and patent-pending bio-photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders. For more information, please visit www.zecotek.com.

This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

For Additional Information Please Contact:

Zecotek Photonics Inc.
Michael Minder
T: (604) 783-8291
ir@zecotek.com
CHF Investor Relations
Julia Clark, Account Manager
T: (416) 868-1079 x236
julia@chfir.com

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.

print